Novo Nordisk Shares Outstanding 2010-2022 | NVO

Novo Nordisk shares outstanding history from 2010 to 2022. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Novo Nordisk shares outstanding for the quarter ending December 31, 2022 were 2.272B, a 1.31% decline year-over-year.
  • Novo Nordisk 2022 shares outstanding were 2.272B, a 1.31% decline from 2021.
  • Novo Nordisk 2021 shares outstanding were 2.302B, a 1.6% decline from 2020.
  • Novo Nordisk 2020 shares outstanding were 2.34B, a 1.63% decline from 2019.
Novo Nordisk Annual Shares Outstanding
(Millions of Shares)
2022 2,272
2021 2,302
2020 2,340
2019 2,379
2018 2,424
2017 2,478
2016 2,535
2015 2,578
2014 2,630
2013 2,694
2012 2,758
2011 2,851
2010 2,927
2009 2,996
Novo Nordisk Quarterly Shares Outstanding
(Millions of Shares)
2022-12-31 2,272
2022-09-30 2,269
2022-06-30 2,273
2022-03-31 2,881
2021-12-31 2,302
2021-09-30 2,297
2021-06-30 2,305
2021-03-31 2,316
2020-12-31 2,340
2020-09-30 2,335
2020-06-30 2,345
2020-03-31 2,355
2019-12-31 2,379
2019-09-30 2,373
2019-06-30 2,384
2019-03-31 2,395
2018-12-31 2,424
2018-09-30 2,419
2018-06-30 2,431
2018-03-31 2,442
2017-12-31 2,478
2017-09-30 2,469
2017-06-30 2,484
2017-03-31 2,500
2016-12-31 2,535
2016-09-30 2,531
2016-06-30 2,541
2016-03-31 2,550
2015-12-31 2,578
2015-09-30 2,572
2015-06-30 2,584
2015-03-31 2,604
2014-12-31 2,630
2014-09-30 2,622
2014-06-30 2,637
2014-03-31 2,653
2013-12-31 2,694
2013-09-30 2,682
2013-06-30 2,703
2013-03-31 2,724
2012-12-31 2,758
2012-09-30 2,739
2012-06-30 2,762
2012-03-31 2,803
2011-12-31 2,810
2011-09-30 2,841
2011-06-30 2,869
2011-03-31 2,884
2010-12-31 2,888
2010-09-30 2,912
2010-06-30 2,945
2010-03-31 2,965
2009-12-31 2,976
2009-09-30 3,007
2009-06-30 3,015
2009-03-31 3,064
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $309.551B $25.059B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $430.370B 16.20
Eli Lilly (LLY) United States $322.186B 42.71
Merck (MRK) United States $260.994B 13.76
AbbVie (ABBV) United States $256.783B 10.65
Pfizer (PFE) United States $247.323B 6.70
Novartis AG (NVS) Switzerland $189.952B 14.05